Session: FP19-Female Reproductive Endocrinology
Room 102 (Moscone Center)
Poster Board SUN-514
Methods: A randomized, double blind placebo controlled study was conducted to investigate the effect of atorvastatin on markers of inflammation including plasma interleukin 6 (IL-6) and tumour necrosis factor α (TNF α) and adipose tissue dysfunction as measured by acylation-stimulating protein (ASP) in women with PCOS. Forty medication naïve patients with PCOS were randomized to either atorvastatin 20 mg daily or placebo for 3 months.
Results: After 12 wk atorvastatin, there was a significant reduction in testosterone (4.1 ± 0.2 vs. 2.9 ± 0.1 nmol/liter, P < 0.01) and insulin resistance as measured by homeostasis model assessment for insulin resistance (HOMA-IR) (3.3 ± 0.4 vs. 2.7 ± 0.4, P < 0.01) and hs-C-reactive protein (4.9 ± 1.4 vs. 3.4 ± 1.1 mg/liter, P = 0.04). There was also a significant reduction in IL-6 levels (1.48 ± 0.09 vs. 0.73 ± 0.10 pg/ml p=0.01) and ASP levels (156.7 ± 10.2 vs. 124.4 ± 9.8 ng/ml p <0.01). There were no significant changes in TNF α levels.
There was a significant positive correlation between D IL-6 levels with D testosterone (r= 0.49, p=0.01) and D hs-CRP (r= 0.5769, p <0.01) and D ASP levels with D testosterone (r= 0.66, p<0.01), hs-CRP (r= 0.52, p=0.01) and HOMA-IR (r= 0.59, p<0.01) after atorvastatin. The reduction in IL-6 levels after atorvastatin treatment positively correlated with D ASP levels (r=0.67, p value=0.01).
On forward stepwise regression analysis, D IL-6 and D ASP accounted for 62.4% of the variance in testosterone change and 52.2% of hs-CRP change with atorvastatin. D ASP accounted for 42.9% of change in HOMA-IR with atorvastatin.
Conclusions: Twelve weeks of atorvastatin treatment led to a significant reduction in surrogate markers of adipocyte inflammation (as determined by IL-6) and adipose tissue dysfunction (as measured by ASP) amongst patients with PCOS. The changes in these markers independently predicted changes in insulin resistance and testosterone after atorvastatin treatment suggesting the beneficial effects of atorvastatin might be mediated through effects on adipose tissue fatty acid metabolism and sub-clinical inflammation.
Nothing to Disclose: TS, SLA, ESK, AMC, JS, JPH, SC, PP, AS, KC
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters